Annexon Inc. Common Stock (ANNX)

About ANNX

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial fo…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

93

Website

annexonbio.com/

Fundamentals

1-day range

$5.39$5.7

Market cap

$917.52M

P/E (trailing)

—

P/E (forward)

-5.45

EPS (trailing)

$-1.20

Dividend yield

—

Beta

1.28

Avg. volume

3.56M

Forecasts

8 analyst ratings

Annexon Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ANNX

  Annexon Inc. Common Stock

  $4.97

  ▼ 5.33%
  Market cap $917.52MP/E —
  $2.03$7.18
• ABUS

  Arbutus Biopharma Corporation Common Stock

  $5.07

  ▼ 1.93%
  Market cap $896.82MP/E 5.61
  $3.5$5.45
• COLL

  Collegium Pharmaceutical Inc. Common Stock

  $25.31

  ▼ 4.27%
  Market cap $944.15MP/E 19.04
  $25.16$50.79
• OMER

  Omeros Corporation Common Stock

  $18.59

  ▼ 3.43%
  Market cap $951.74MP/E 14.37
  $3.94$19.65
• AMPH

  Amphastar Pharmaceuticals Inc. Common Stock

  $22.01

  ▲ 0.59%
  Market cap $873.48MP/E 10.93
  $16.65$31.26
• DSGN

  Design Therapeutics Inc. Common Stock

  $15.12

  ▼ 0.85%
  Market cap $861.75MP/E —
  $5.04$17.25
• JANX

  Janux Therapeutics Inc. Common Stock

  $18.01

  ▼ 4.10%
  Market cap $981.85MP/E —
  $12.12$35.34

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Citizens Upgrades Annexon to Market Perform
  Benzinga · 8/13/2026
• Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/12/2026
• Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate
  Benzinga · 8/12/2026
• Annexon Adds Month 24 Dual Primary Endpoint To Complement Current Month 15 Primary Endpoint In Phase 3 ARCHER II Trial And Launches OLE Study Of Vonaprument For Treatment Of Dry AMD With Geographic Atrophy
  Benzinga · 8/12/2026
• Annexon Reports Early Strength Improvement And Clinically Meaningful Disability Reduction With Tanruprubart In First Ten US And European Guillain-Barré Syndrome Patients From Ongoing FORWARD Study
  Benzinga · 8/6/2026
• Reported July 30: Annexon Inks $200M Credit Facility Agreement With Oxford Finance
  Benzinga · 7/31/2026

• Blumenkranz Mark S. · August 10, 2026 · Grant

  175.0K
• Cockroft Bettina M. · June 11, 2026 · Grant

  65.0K
• William H. Carson · June 11, 2026 · Grant

  65.0K
• Ted Yednock · June 11, 2026 · Option Exercise

  30.6K @ $1.85
• Jung Choi · June 11, 2026 · Grant

  65.0K
• William D. Waddill · June 11, 2026 · Grant

  65.0K
• JONES WILLIAM A JR · June 11, 2026 · Grant

  65.0K
• Muneer A. Satter · June 11, 2026 · Grant

  65.0K
• Muneer A. Satter · May 28, 2026 · Buy

  613.5K @ $5.41
• William H. Carson · May 11, 2026 · Buy

  8.0K @ $5.78
• William H. Carson · April 10, 2026 · Buy

  8.0K @ $6.2
• William H. Carson · March 10, 2026 · Buy

  8.0K @ $5.67
• Dean Richard Artis · March 2, 2026 · Sale

  5.9K @ $5.43
• Ted Yednock · March 2, 2026 · Sale

  5.6K @ $5.42
• Michael Overdorf · March 2, 2026 · Sale

  4.3K @ $5.42

Institutional Ownership

March 31, 2026

Total shares held

154.11M

Total value held

$845.78M

Institutional holders

210